Showing results (121-130 of 134) with videos related to
Sort By:
Pageof 14
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|April 17, 2025
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)Nargiz Majidova, Sendag Yaslıkaya, Maral Martin Mıldanoglu, et al.Medicine|November 14, 2023
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from TurkeyArif Akyildiz, Deniz Can Guven, Ahmet Anil Ozluk, et al.Expert Review of Anticancer Therapy|January 9, 2026
Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancerEmel Mutlu Ozkan, Ibrahim Karadağ, Elif Sahın, et al.Scientific Reports|May 8, 2026
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patientsMuhammet Cengiz, Oktay Bozkurt, Ayse Nuransoy Cengiz, et al.BMC Cancer|December 30, 2024
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studySeda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, et al.Journal of Chemotherapy (Florence, Italy)|September 11, 2024
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaHasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, et al.Frontiers in Immunology|December 26, 2025
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter studyTaha Koray Sahin, Fatih Atalah, Bahadir Koylu, et al.Journal of Chemotherapy (Florence, Italy)|January 24, 2024
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencingOsman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, et al.Therapeutic Advances in Medical Oncology|March 16, 2026
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studyTaha Koray Sahin, Fatih Kemik, Harun Muglu, et al.Journal of Clinical Medicine|February 27, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective AnalysisBaris Koksal, Hasan Cagri Yildirim, Deniz Can Guven, et al.Pageof 14